Cumberland Pharmaceuticals Total Assets Growth & History (CPIX)
Cumberland Pharmaceuticals's total assets was $76.8M for fiscal 2025.
View full Cumberland Pharmaceuticals company overviewCumberland Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $76.8M | $1.2M | +1.64% |
| 2024 | 2024-12-31 | $75.6M | −$6.2M | −7.57% |
| 2023 | 2023-12-31 | $81.8M | −$11.1M | −12.00% |
| 2022 | 2022-12-31 | $92.9M | $8.5M | +10.02% |
| 2021 | 2021-12-31 | $84.5M | −$12.0M | −12.44% |
| 2020 | 2020-12-31 | $96.5M | −$8.1M | −7.73% |
| 2019 | 2019-12-31 | $104.5M | −$8.1M | −7.23% |
| 2018 | 2018-12-31 | $112.7M | $19.5M | +20.87% |
| 2017 | 2017-12-31 | $93.2M | −$172,254 | −0.18% |
| 2016 | 2016-12-31 | $93.4M | $1.5M | +1.62% |
| 2015 | 2015-12-31 | $91.9M | −$3.5M | −3.65% |
| 2014 | 2014-12-31 | $95.4M | $7.8M | +8.89% |
| 2013 | 2013-12-31 | $87.6M | −$11.0M | −11.14% |
| 2012 | 2012-12-31 | $98.6M | $3.1M | +3.22% |
| 2011 | 2011-12-31 | $95.5M | $3.5M | +3.76% |
| 2010 | 2010-12-31 | $92.1M | — | — |
Cumberland Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $62.9M | −$5.0M | −7.40% |
| Q1 2026 | 2026-03-31 | $71.0M | $1.1M | +1.51% |
| Q4 2025 | 2025-12-31 | $76.8M | $1.2M | +1.64% |
| Q3 2025 | 2025-09-30 | $65.9M | −$10.8M | −14.14% |
| Q2 2025 | 2025-06-30 | $67.9M | −$10.6M | −13.52% |
| Q1 2025 | 2025-03-31 | $69.9M | −$11.6M | −14.20% |
| Q4 2024 | 2024-12-31 | $75.6M | −$6.2M | −7.57% |
| Q3 2024 | 2024-09-30 | $76.7M | −$11.0M | −12.54% |
| Q2 2024 | 2024-06-30 | $78.5M | −$10.9M | −12.15% |
| Q1 2024 | 2024-03-31 | $81.5M | −$8.0M | −8.90% |
| Q4 2023 | 2023-12-31 | $81.8M | −$11.1M | −12.00% |
| Q3 2023 | 2023-09-30 | $87.8M | −$3.0M | −3.33% |
| Q2 2023 | 2023-06-30 | $89.4M | −$3.1M | −3.40% |
| Q1 2023 | 2023-03-31 | $89.5M | −$7.2M | −7.48% |
| Q4 2022 | 2022-12-31 | $92.9M | $8.5M | +10.02% |
| Q3 2022 | 2022-09-30 | $90.8M | $3.2M | +3.66% |
| Q2 2022 | 2022-06-30 | $92.5M | $3.7M | +4.13% |
| Q1 2022 | 2022-03-31 | $96.7M | $3.3M | +3.59% |
| Q4 2021 | 2021-12-31 | $84.5M | −$12.0M | −12.44% |
| Q3 2021 | 2021-09-30 | $87.6M | −$8.4M | −8.79% |
| Q2 2021 | 2021-06-30 | $88.9M | −$8.7M | −8.89% |
| Q1 2021 | 2021-03-31 | $93.3M | −$4.1M | −4.18% |
| Q4 2020 | 2020-12-31 | $96.5M | −$8.1M | −7.73% |
| Q3 2020 | 2020-09-30 | $96.0M | −$7.8M | −7.47% |
| Q2 2020 | 2020-06-30 | $97.5M | −$10.0M | −9.32% |
| Q1 2020 | 2020-03-31 | $97.4M | −$17.2M | −15.01% |
| Q4 2019 | 2019-12-31 | $104.5M | −$8.1M | −7.23% |
| Q3 2019 | 2019-09-30 | $103.8M | $16.3M | +18.68% |
| Q2 2019 | 2019-06-30 | $107.5M | $17.1M | +18.91% |
| Q1 2019 | 2019-03-31 | $114.6M | $23.5M | +25.82% |
| Q4 2018 | 2018-12-31 | $112.7M | $19.5M | +20.87% |
| Q3 2018 | 2018-09-30 | $87.4M | −$2.9M | −3.23% |
| Q2 2018 | 2018-06-30 | $90.4M | $2.6M | +3.01% |
| Q1 2018 | 2018-03-31 | $91.1M | −$766,765 | −0.83% |
| Q4 2017 | 2017-12-31 | $93.2M | −$172,254 | −0.18% |
| Q3 2017 | 2017-09-30 | $90.4M | −$723,214 | −0.79% |
| Q2 2017 | 2017-06-30 | $87.8M | −$86,138 | −0.10% |
| Q1 2017 | 2017-03-31 | $91.9M | $2.7M | +2.98% |
| Q4 2016 | 2016-12-31 | $93.4M | $1.5M | +1.62% |
| Q3 2016 | 2016-09-30 | $91.1M | −$984,966 | −1.07% |
| Q2 2016 | 2016-06-30 | $87.9M | −$5.0M | −5.41% |
| Q1 2016 | 2016-03-31 | $89.2M | −$3.0M | −3.24% |
| Q4 2015 | 2015-12-31 | $91.9M | −$3.5M | −3.65% |
| Q3 2015 | 2015-09-30 | $92.1M | −$1.8M | −1.96% |
| Q2 2015 | 2015-06-30 | $92.9M | −$551,937 | −0.59% |
| Q1 2015 | 2015-03-31 | $92.2M | $1.1M | +1.19% |
| Q4 2014 | 2014-12-31 | $95.4M | $7.8M | +8.89% |
| Q3 2014 | 2014-09-30 | $93.9M | $2.0M | +2.17% |
| Q2 2014 | 2014-06-30 | $93.5M | −$2.0M | −2.09% |
| Q1 2014 | 2014-03-31 | $91.1M | −$7.2M | −7.30% |
| Q4 2013 | 2013-12-31 | $87.6M | −$11.0M | −11.14% |
| Q3 2013 | 2013-09-30 | $91.9M | −$5.0M | −5.18% |
| Q2 2013 | 2013-06-30 | $95.5M | $85,014 | +0.09% |
| Q1 2013 | 2013-03-31 | $98.3M | $3.7M | +3.92% |
| Q4 2012 | 2012-12-31 | $98.6M | $3.1M | +3.22% |
| Q3 2012 | 2012-09-30 | $96.9M | $855,130 | +0.89% |
| Q2 2012 | 2012-06-30 | $95.4M | $799,541 | +0.85% |
| Q1 2012 | 2012-03-31 | $94.6M | — | — |
| Q4 2011 | 2011-12-31 | $95.5M | $3.5M | +3.76% |
| Q3 2011 | 2011-09-30 | $96.1M | — | — |
| Q2 2011 | 2011-06-30 | $94.6M | — | — |
| Q4 2010 | 2010-12-31 | $92.1M | — | — |
Cumberland Pharmaceuticals total assets trends
Over the last five fiscal years, Cumberland Pharmaceuticals's total assets decreased from $96.5M to $76.8M, a change of −$19.6M. The latest reported quarter, Q2 2026, shows $62.9M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cumberland Pharmaceuticals source filings ↗